强度疗法公司美股招股说明书(2025-12-04版)

Up to $30,000,000 Common Stock We have previously entered into an at the market offering agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC(“Wainwright”) relating to shares of our common stock offered by this prospectus supplement and the sales agreement prospectusdated July 11, 2024 (the “July 11, 2024 sales agreement prospectus”) and the base prospectus dated July 11, 2024 (the “July 11, 2024prospectus”). In accordance with the terms of the Offering Agreement, we may offer and sell shares of our common stock, $0.0001 par Our common stock is listed on The Nasdaq Capital Market under the symbol “INTS.” On December 3, 2025, the last reported saleprice of our common stock on The Nasdaq Capital Market was $0.4098 per share. We are filing this prospectus supplement to supplement and amend, as of December 4, 2025, the July 11, 2024 sales agreementprospectus and July 11, 2024 base prospectus to increase the maximum aggregate gross sales price of our common stock that may beoffered, issued and sold under the Offering Agreement from and after the date hereof to $30,000,000 (the “ATM Offering SizeIncrease”), not including the shares of common stock previously sold. Under the July 11, 2024 sales agreement prospectus, we initiallyregistered up to $15,000,000 of our common stock for offer and sale pursuant to the Offering Agreement, which was reduced to$7,000,000 on November 20, 2024, further reduced to $15,000 on June 11, 2025, and then increased to $9,650,000 pursuant to the The purpose of this prospectus supplement is to update the July 11, 2024 sales agreement prospectus to reflect the ATM Offering SizeIncrease. Except as modified by this prospectus supplement, the terms of the ATM Offering remain unchanged, and the Offering The July 11, 2024 sales agreement prospectus and July 11, 2024 base prospectus and prior prospectus supplements dated November20, 2024, June 11, 2025 and June 18, 2025, respectively, indicated that we were, at that time, subject to General Instruction I.B.6. ofForm S-3, which limited the amount that we were able to sell under the registration statement of which the prospectus forms a part. Weare currently no longer subject to the offering limits imposed by General Instruction I.B.6. of Form S-3. As of the date of thisprospectus supplement, the aggregate market value of our outstanding shares of common stock held by non-affiliates, wasapproximately $76,499,742, which was calculated based on our 57,954,350 outstanding shares of common stock held by non-affiliates Our business and an investment in our common stock involve significant risks. These risks are described under the caption“Risk Factors” beginning on pagesS-6 and5of the July 11, 2024 sales agreement prospectus and July 11, 2024 baseprospectus, respectively, and in the documents incorporated by reference into the July 11, 2024 sales agreement prospectus and Neither the SEC nor any state securities commission has approved of anyone’s investment in these securities or determined ifthis prospectus supplement, the July 11, 2024 sales agreement prospectus and July 11, 2024 base prospectus are truthful or H.C. Wainwright & Co. The date of this prospectus supplement is December 4, 2025.